Skip to main content

Advertisement

SpringerLink
Log in

The immune checkpoint inhibitors: where are we now?

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Major-market sales of select immune checkpoint inhibitors (estimated).

References

  1. Decision Resources Group: Malignant Melanoma. Pharmacor Service. Onkos. 2013–2014.

  2. Decision Resources Group: NSCLC. Pharmacor Service. Onkos. 2013–2014.

  3. Decision Resources Group: Pharmaview Service. 2014.

  4. Decision Resources Group: Immunotherapies. Pharmacor Service. Onkos. 2014.

Download references

Author information

Authors and Affiliations

  1. Rachel Webster is at Decision Resources, 6th Floor, Aldermary House, 1015 Queen Street, London EC4N 1TX, United Kingdom.,

    Rachel M. Webster

Authors
  1. Rachel M. Webster
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rachel M. Webster.

Ethics declarations

Competing interests

The author declares no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Webster, R. The immune checkpoint inhibitors: where are we now?. Nat Rev Drug Discov 13, 883–884 (2014). https://doi.org/10.1038/nrd4476

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4476

  • Springer Nature Limited

This article is cited by

Search

Navigation